These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Pathogenesis of Guillain-Barré syndrome. Hughes RA; Hadden RD; Gregson NA; Smith KJ J Neuroimmunol; 1999 Dec; 100(1-2):74-97. PubMed ID: 10695718 [TBL] [Abstract][Full Text] [Related]
9. Acute and chronic neuropathies: new aspects of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, an overview and an update. Trojaborg W Electroencephalogr Clin Neurophysiol; 1998 Nov; 107(5):303-16. PubMed ID: 9872432 [TBL] [Abstract][Full Text] [Related]
18. Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Bergin PS; Miller DH; Hirsch NP; Murray NM Ann Neurol; 1993 Sep; 34(3):406-9. PubMed ID: 8363359 [TBL] [Abstract][Full Text] [Related]
19. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. van der Meché FG; van Doorn PA Ann Neurol; 1995 May; 37 Suppl 1():S14-31. PubMed ID: 8968214 [TBL] [Abstract][Full Text] [Related]
20. Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain-Barré syndrome. Yako K; Kusunoki S; Kanazawa I J Neurol Sci; 1999 Oct; 168(2):85-9. PubMed ID: 10526188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]